Literature DB >> 22039254

A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.

Kathryn T Bieging1, Kamonwan Fish, Subbarao Bondada, Richard Longnecker.   

Abstract

The link between EBV infection and Burkitt lymphoma (BL) is strong, but the mechanism underlying that link has been elusive. We have developed a mouse model for EBV-associated BL in which LMP2A, an EBV latency protein, and MYC are expressed in B cells. Our model has demonstrated the ability of LMP2A to accelerate tumor onset, increase spleen size, and bypass p53 inactivation. Here we describe the results of total gene expression analysis of tumor and pretumor B cells from our transgenic mouse model. Although we see many phenotypic differences and changes in gene expression in pretumor B cells, the transcriptional profiles of tumor cells from LMP2A/λ-MYC and λ-MYC mice are strikingly similar, with fewer than 20 genes differentially expressed. We evaluated the functional significance of one of the most interesting differentially expressed genes, Egr1, and found that it was not required for acceleration of tumor onset by LMP2A. Our studies demonstrate the remarkable ability of LMP2A to affect the pretumor B-cell phenotype and tumorigenesis without substantially altering gene expression in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22039254      PMCID: PMC3245207          DOI: 10.1182/blood-2011-02-338434

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt.

Authors:  F Scholle; K M Bendt; N Raab-Traub
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.

Authors:  R Swart; I K Ruf; J Sample; R Longnecker
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.

Authors:  R G Caldwell; R C Brown; R Longnecker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Granulocyte colony-stimulating factor induces Egr-1 up-regulation through interaction of serum response element-binding proteins.

Authors:  P Mora-Garcia; K M Sakamoto
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

6.  Impaired prostate tumorigenesis in Egr1-deficient mice.

Authors:  S A Abdulkadir; Z Qu; E Garabedian; S K Song; T J Peters; J Svaren; J M Carbone; C K Naughton; W J Catalona; J J Ackerman; J I Gordon; P A Humphrey; J Milbrandt
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

7.  The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling.

Authors:  T Virolle; E D Adamson; V Baron; D Birle; D Mercola; T Mustelin; I de Belle
Journal:  Nat Cell Biol       Date:  2001-12       Impact factor: 28.824

8.  Epidermal growth factor and thrombin induced proliferation of immortalized human keratinocytes is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator.

Authors:  Katrin Kaufmann; Gerald Thiel
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

9.  Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma.

Authors:  A E Thigpen; K M Cala; J M Guileyardo; K H Molberg; J D McConnell; D W Russell
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

10.  Burkitt lymphoma in the mouse.

Authors:  A L Kovalchuk; C F Qi; T A Torrey; L Taddesse-Heath; L Feigenbaum; S S Park; A Gerbitz; G Klobeck; K Hoertnagel; A Polack; G W Bornkamm; S Janz; H C Morse
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

View more
  7 in total

1.  Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Authors:  Kamonwan Fish; Jia Chen; Richard Longnecker
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

Review 2.  Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.

Authors:  Zeina Al-Mansour; Beverly P Nelson; Andrew M Evens
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

3.  EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice.

Authors:  Kamonwan Fish; Richard P Sora; Samantha J Schaller; Richard Longnecker; Masato Ikeda
Journal:  Blood       Date:  2017-10-26       Impact factor: 22.113

4.  Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.

Authors:  Alexandra C Vrazo; Maria Chauchard; Nancy Raab-Traub; Richard Longnecker
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823

5.  Two Pathways of p27Kip1 Degradation Are Required for Murine Lymphoma Driven by Myc and EBV Latent Membrane Protein 2A.

Authors:  Richard P Sora; Masato Ikeda; Richard Longnecker
Journal:  mBio       Date:  2019-04-16       Impact factor: 7.867

6.  Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.

Authors:  Masato Ikeda; Cooper K Hayes; Samantha J Schaller; Richard Longnecker
Journal:  Blood Adv       Date:  2022-07-26

7.  Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile.

Authors:  Weihua Tang; Douglas R Morgan; Michael O Meyers; Ricardo L Dominguez; Enrique Martinez; Kennichi Kakudo; Pei Fen Kuan; Natalie Banet; Hind Muallem; Kimberly Woodward; Olga Speck; Margaret L Gulley
Journal:  Infect Agent Cancer       Date:  2012-08-28       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.